An *in silico* approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors

Arun Bahadur Gurunga, Mohammad Ajmal Ali, Mohamed S. Elshikh, Ibrahim Aref, Musarat Amina, Joongku Lee

*Department of Basic Sciences and Social Sciences, North-Eastern Hill University, Shillong 793022, Meghalaya, India*

*Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia*

*Department of Pharmacognosy, Pharmacy College, King Saud University, Riyadh 11451, Saudi Arabia*

*Department of Environment and Forest Resources, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea*

**Abstract**

The increased transmissibility and highly infectious nature of the new variant of concern (VOC) that is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and lack of effective therapy need the rapid discovery of therapeutic antivirals against it. The present investigation aimed to identify antiviral compounds that would be effective against SARS-CoV-2 Omicron. In this study, molecular docking experiments were carried out using the recently reported experimental structure of omicron spike protein in complex with human angiotensin-converting enzyme 2 (ACE2) and various antivirals in preclinical and clinical trial studies. Out of 36 tested compounds, Abemaciclib, Dasatinib and Spiperone are the three top-ranked molecules which scored binding energies of $-10.08$ kcal/mol, $-10.06$ kcal/mol and $-9.54$ kcal/mol respectively. Phe338, Asp339, and Asp364 are crucial omicron receptor residues involved in hydrogen bond interactions, while other residues were mostly involved in hydrophobic interactions with the lead molecules. The identified lead compounds also scored well in terms of drug-likeness. Molecular dynamics (MD) simulation, essential dynamics (ED) and entropic analysis indicate the ability of these molecules to modulate the activity of omicron spike protein. Therefore, Abemaciclib, Dasatinib and Spiperone are likely to be viable drug-candidate molecules that can block the interaction between the omicron spike protein and the host cellular receptor ACE2. Though our findings are compelling, more research into these molecules is needed before they can be employed as drugs to treat SARS-CoV-2 omicron infections.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The increased daily reported cases of coronavirus disease 2019 (COVID-19) due to the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has added further to the global health crisis. This new variant of concern (VOC) was first detected on November, 1 in Botswana and reported to the World Health Organization (WHO) on November 26, 2021. Since then, it has rapidly spread to at least 38 countries (WHO Classification of Omicron (B.1.1.529), 2021). Omicron features a few deletions and over 30 mutations, some of which (e.g., 69–70del, T95I, G142D/143–145del, K417N, T478K, N501Y, N655Y, N679K, and P681H) overlap with those seen in the alpha, beta, gamma, or delta VOC (GISAID, 2021). These deletions and mutations have been linked to its increased transmissibility, stronger viral binding affinity, and antibody escape. Other known omicron mutations include those that improve transmissibility and alter binding affinity (Greaney et al., 2021; Harvey et al., 2021). Unfortunately, the implications of the majority of the remaining omicron mutations are unknown, leaving a lot of questions about how the whole set of deletions and mutations may affect viral behaviour and vulnerability to natural and vaccine-mediated immunity (Karim and Karim, 2021). This fifth VOC is considered to be three times more contagious than the original SARS-CoV-2 and maybe even more so than the delta variant (Gao et al., 2021).

https://doi.org/10.1016/j.sjbs.2022.103297
1319-562X/© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Computational drug discovery is a successful technique for speeding up and reducing the cost of drug development. The applicability of computational drug discovery has been extended and broadly applied to nearly every stage in the drug discovery and development workflow, including target identification and validation, lead discovery and optimization, and preclinical tests, due to the dramatic increase in the availability of biological macromolecule and small molecule information (Ou-Yang et al., 2012). One of the most extensively utilised structure-based drug design (SBDD) methods is virtual screening based on molecular docking. The molecular docking approach may be used to represent the atomic level interaction between a small molecule and a protein, allowing us to define small molecule behaviour in target protein binding sites and elucidate essential biochemical processes (McConkey et al., 2002). The technique is becoming increasingly popular in computer-aided drug design as more biomolecular structures are being submitted to the protein data bank and made freely available. However, standard molecular docking approaches do not take into account the target’s flexibility, which could lead to the omission of some active molecules. Molecular dynamics (MD) simulations, on the other hand, may obtain numerous target conformations and have been frequently employed in molecular docking to account for target flexibility (Liu et al., 2018). MD simulations paired with binding free energy estimates have also been found to be an effective technique for increasing the enrichment factor of virtual screening by improving the accuracy of target–ligand binding ability prediction (Rastelli et al., 2010). The recently solved experimental structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (PDB ID: 7WBL) (Han et al., 2022) offers an opportunity to identify small molecule inhibitors. The transmembrane spike (S) glycoprotein, which forms homo-trimers projecting from the viral surface, is responsible for coronavirus (CoV) entry into host cells (Tortorici and Veesler, 2019). S is made up of two functional subunits that are responsible for viral and cellular membrane fusion (S1 subunit) as well as binding to the host cell receptor (S2 subunit). S is cleaved at the interface between the S1 and S2 subunits in many CoVs, although they remain non-covalently coupled in the prefusion conformation (Kirchdoerfer et al., 2016; Walls et al., 2016). S is cleaved further by host proteases at the so-called S2′ site, which is positioned immediately upstream of the fusion peptide in all CoVs (Madu et al., 2009; Millet and Whittaker, 2015). It’s been suggested that this cleavage prepares the protein for membrane fusion by causing substantial irreversible conformational changes (Park et al., 2016). The coronavirus S glycoprotein is the principal target of neutralising antibodies (Abs) and the focus of therapeutic and vaccine design because it is surface-exposed and mediates viral entry into host cells (Walls et al., 2020). In this study, we have used the molecular docking technique and molecular dynamics simulations to screen small antiviral molecules which can effectively bind to the omicron spike protein and hinder its interaction with the host cellular receptor. We have proposed a few molecules which may be developed into antiviral drugs against omicron.

2. Materials and methods

2.1. Retrieval of ligands and protein structure

A total of 36 compounds with preclinical or clinical trial evidence against previous variants of SARS-CoV-2 were selected for the study (Xiang et al., 2021). The three-dimensional structures of the compounds were obtained from the PubChem database (Kim et al., 2016). The compounds with the 2D structure were converted into the 3D structure using OpenBabel version 2.4.1 (O’Boyle et al., 2011). The structural optimization of the compounds was performed using the Merck molecular force field 94 (MMFF94) (Halgren, 1996). The three-dimensional structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 was retrieved from protein data bank (PDB) using accession PDB ID: 7WBL (Han et al., 2022). The cryogenic electron microscopy (cryo-EM) structure has been resolved at a resolution of 3.40 Å.

2.2. Evaluation of interface statistics of a complex between omicron spike protein and human ACE2

The protein–protein interface statistics such as interface residues, interface area, hydrogen bonds, disulphide bonds and non-bonded contacts were evaluated using the PDBeSum program (Laskowski, 2009).

2.3. Preparation of ligands and protein

Each compound was prepared for molecular docking experiments by the addition of Gasteiger charges, hydrogen atoms and optimally defined torsions using AutoDock Tools-1.5.6 (Morris et al., 2009). The heteroatoms, including ions, co-crystallized ligand and water molecules, were removed from the Omicron spike protein. AutoDockTools-1.5.6 tool (Morris et al., 2009) was used for adding a suitable number of polar hydrogen atoms and Kollman charges to the target protein.

2.4. Molecular docking

The Lamarckian genetic algorithm was employed for molecular docking experiments where the docking parameters were selected from our previously reported methodology (Gurung, 2020). AutoDock4.2 software was used to perform blind molecular docking (Morris et al., 2009) The binding site of the compounds was defined by choosing a grid box centred at the omicron spike protein with XYZ coordinates of 79.4618, 96.1430 and 124.0359, number of grid points of 96 × 141 × 154 and grid spacing of 0.375 Å. For each compound, a total of fifty separate docking runs were performed. The docking poses were conformationally clustered using a root mean square deviation (RMSD) cut-off value of 2.0 Å. The most favourable binding poses of the compounds were explored by determining the lowest binding free energy (ΔG). The hydrogen bonds and hydrophobic interactions between the compounds and the target protein were investigated using the LigPLOT® v.1.4.5 tool (Laskowski and Swindells, 2011).

2.5. Evaluation of physicochemical properties of compounds

The DataWarrior version 4.6.1 program was used to determine the physicochemical characteristics of the compounds (Sander et al., 2015).

2.6. Molecular dynamics simulations

GRoningen MAchine for Chemical Simulations (GROMACS) 2019.2 software (Hess et al., 2008) with the GROMOS96 43a1 force field was used to run 100-ns MD simulations on the free omicron spike protein and its complexes with lead molecules. Using a three-point model for water termed simple point charge (SPC216), the systems were solvated in a water-filled 3-D cube with 1 Å spacing. A leap-frog temporal integration technique was used to integrate Newton’s equations of motion. The systems were neutralised, and the quantity of energy used was optimised. The temperature was set to 300 K, and the systems were equilibrated for 300 ps in the NVT (NumberOf particles, Volume, and Temperature) ensemble, and another 300 ps in the NPT (NumberOf particles, Pressure, and Temperature) ensemble.
hydrophobic interactions and hydrogen bonds. For example, Abemaciclib binds to the spike protein through hydrophobic interactions with Tyr365, Leu368, Tyr369, Asn370, Phe374, Phe377, Cys379, Val382, Ser383, Pro384, Leu387, Asn388, Cys432, Ile434 and Phe515 (Fig. 2A). The second lead Dasatinib binds to spike protein with four hydrogen bonds—a 2.79 Å length hydrogen bond with O atom of Asp364, 2.90 Å and 2.76 Å length hydrogen bonds with OD1 atom of Asp339 and a 3.05 Å hydrogen bond with O atom of Arg457 and hydrophobic interactions with Phe342, Tyr365, Leu368, Pro373, Phe374, Phe377, Cys432, Ile434, Trp436 and Leu513 (Fig. 2B). The third lead molecule Spiperone binds to the spike protein receptor through hydrophobic interactions with Phe318, Asp339, Asp364, Tyr365, Val367, Leu368, Tyr369, Phe377, Pro384, Cys432, Ile434 and Leu513 (Fig. 2C). The compounds were also evaluated for their oral bioavailability which includes parameters such as molecular weight (MW), LogP (partition coefficient between n-octanol and water), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), rotatable bond (RB) count, topological polar surface area (TPSA) and drug-likeness scores (Table 3). All the three identified lead molecules—Abemaciclib, Dasatinib and Spiperone show good drug-likeness scores of 6.2983, 8.0376 and 9.9352 respectively. Although Abemaciclib’s molecular weight exceeds 500, its other physicochemical properties are within the permissible range of Lipinski’s rule of five (Lipinski, 2004) and Veber’s rule (Veber et al., 2002), and the other two lead compounds, Dasatinib and Spiperone, totally obey these two drug-likeness rules.

The conformational changes and stability of the free omicron spike protein and its complexes with the top three lead compounds (Abemaciclib, Dasatinib, and Spiperone) were investigated using a

2.7. Essential dynamics

Essential dynamics (ED), also known as principal component analysis (PCA), was investigated by diagonalizing a covariance matrix of C-α atoms of the system. Eigenvectors were used to define the directions of massive coordinated motions, and the eigenvalues corresponded to mean-square positional fluctuation (Amadei et al., 1993).

3. Results

A total of 36 small molecule inhibitors with preclinical and clinical trial data against COVID-19 were selected for the present study (Table 1). The rationale behind the selection of these molecules is to see if they work against the omicron variant of SARS-CoV-2 as well. We have utilised the very recently reported experimental structure of omicron SARS-CoV-2 spike with human ACE2 receptor for our studies. PDBsum analysis reveals that the protein–protein complex is stabilized through one salt bridge, ten hydrogen bonds and 87 non-bonded contacts (Table 2). The interaction of omicron spike protein to ACE2 involves Ser19, Gln24, Thr27, Phe28, Lys31, His34, Glu35, Asp38, Tyr41, Gln42 Leu79, Met82, Tyr83, Arg357 of ACE2 and Tyr449, Arg493, Tyr453, His34, Glu35, Asp38, Tyr41, Gln42, Leu79, Met82, Tyr83, Lys353, Leu455, Phe456, Ala475, Gly476, Asn477, Phe486, Asn487, Tyr489, Ser496, Arg498, Thr500, Tyr501, Gly502 and His505 of spicke protein to ACE2 involves Ser19, Gln24, Thr27, Phe28, Lys31, His34, Glu35, Asp38, Tyr41, Gln42 Leu79, Met82, Tyr83, Arg357 of ACE2 and Tyr449, Arg493, Tyr453, His34, Glu35, Asp38, Tyr41, Gln42, Leu79, Met82, Tyr83, Lys353, Leu455, Phe456, Ala475, Gly476, Asn477, Phe486, Asn487, Tyr489, Ser496, Arg498, Thr500, Tyr501, Gly502 and His505 of omicron spike protein (Fig. 1). The top 3 lead molecules which show considerable binding affinity to the omicron spike protein receptor include Abemaciclib (ΔG = −10.08 kcal/mol), Dasatinib (ΔG = −10.06 kcal/mol) and Spiperone (ΔG = −9.54 kcal/mol) (Table 1). These molecules bind to the spike interface region

### Table 1

| S No. | compounds             | Known molecular targets | PubChem CID   | Binding Energy (kcal/mol) |
|-------|-----------------------|-------------------------|---------------|--------------------------|
| 1     | Salvianolic acid C     | Entry inhibitors         | 13991590      | −5.82                    |
| 2     | Arbidol               | Entry inhibitors         | 1314111       | −4.99                    |
| 3     | Cepharanthine         | Entry inhibitors         | 10206         | −7                       |
| 4     | Abemaciclib           | Entry inhibitors         | 46220502      | −5.74                    |
| 5     | Duanetinib            | Entry inhibitors         | 71466458      | −5.47                    |
| 6     | Trimipramine          | Entry inhibitors         | 5584          | −5.8                     |
| 7     | Colforsin             | Entry inhibitors         | 479396        | −6.38                    |
| 8     | Ingenol               | Entry inhibitors         | 4420042       | −6.07                    |
| 9     | Clodazimine           | Entry inhibitors         | 2794          | −6.33                    |
| 10    | Tafenoquine           | 3CL<sup>+</sup> inhibitors | 115358        | −4.77                    |
| 11    | Baicalin              | 3CL<sup>+</sup> inhibitors | 64982         | −5.71                    |
| 12    | Baicalein             | 3CL<sup>+</sup> inhibitors | 5281605      | −7.45                    |
| 13    | Cinanserin            | 3CL<sup>+</sup> inhibitors | 5475158      | −5.3                     |
| 14    | GC373                 | 3CL<sup>+</sup> inhibitors | 78225172     | −5.07                    |
| 15    | Boceprevir            | 3CL<sup>+</sup> inhibitors | 10324367     | −5.01                    |
| 16    | Bepidil               | 3CL<sup>+</sup> inhibitors | 2351         | −4.67                    |
| 17    | Nelfinavir mesylate   | 3CL<sup>+</sup> inhibitors | 64142        | −5.32                    |
| 18    | Z-FA-FMK              | 3CL<sup>+</sup> inhibitors | 5311161      | −5.07                    |
| 19    | Suramin               | 3CL<sup>+</sup> inhibitors | 5361         | −9.51                    |
| 20    | Lopinavir             | 3CL<sup>+</sup> inhibitors | 92277        | −4.86                    |
| 21    | Ritonavir             | 3CL<sup>+</sup> inhibitors | 392622       | −3.57                    |
| 22    | Dipyridamole          | 3CL<sup>+</sup> inhibitors | 3108         | −2.05                    |
| 23    | Dasatinib             | PE<sup>+</sup> inhibitors | 3062316      | −6.45                    |
| 24    | Dronedarone           | PE<sup>+</sup> inhibitors | 208898       | −5.23                    |
| 25    | Remdesivir            | RdRp inhibitors          | 121304016    | −3.17                    |
| 26    | Favipiravir           | RdRp inhibitors          | 492405       | −4.56                    |
| 27    | Dolastegravir         | RdRp inhibitors          | 54726191     | −7.21                    |
| 28    | n-D-N4-Hydroxyxycitidine (EDD-1931) | RdRp inhibitors | 197020 | −5.39 |
| 29    | Tipranavir            | Other small molecule inhibitors | 54682461   | −5.42                    |
| 30    | Saquinavir            | Other small molecule inhibitors | 441243     | −5.93                    |
| 31    | Atazanavir            | Other small molecule inhibitors | 148192      | −4.31                    |
| 32    | Azithromycin          | Other small molecule inhibitors | 447043     | −3.2                     |
| 33    | Spiperone             | Other small molecule inhibitors | 5265       | −6.76                    |
| 34    | Alprostadil           | Other small molecule inhibitors | 5280723    | −6.23                    |
| 35    | Ivermectin            | Other small molecule inhibitors | 6321424    | −6.95                    |
| 36    | Penciclovir           | Other small molecule inhibitors | 13539874    | −5.17                    |
100-ns molecular dynamics simulation in an aqueous environment. The geometric parameters of the systems were computed from their trajectories, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), the radius of gyration (Rg), solvent accessible surface area (SASA), and the number of hydrogen bonds (NHBs) (Table 4). The RMSD is a typical way of determining the structural distance between coordinates which allows us to calculate the average distance between atoms in a group (e.g. backbone atoms of a protein). The average RMSD of the backbone atoms of free omicron spike protein, Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone complex were 0.278901594 ± 0.031966157 nm, 0.328851582 ± 0.025975243 nm, 0.308323815 ± 0.035772956 nm and 0.39048016 ± 0.042679318 nm respectively (Fig. 3A). This indicates that the compounds bind to the omicron spike protein, causing larger amplitudes of fluctuations. The average RMSD of the heavy atoms of the compounds-Abemaciclib, Dasatinib and Spiperone were found to be 0.396129844 ± 0.067303045 nm, 0.295270837 ± 0.09276118 nm and 0.752636825 ± 0.203613952 nm respectively (Fig. 3B) which suggests that the compounds did not undergo large conformational changes due to their stability within the active pocket of the omicron spike protein. RMSF is a measurement of a particle’s average variation from a reference position over time. The RMSF plot shows stable fluctuations in free omicron spike protein and its complexes except for positions 483–486 and 527 in Omicron spike_Spiperone complex and residue 519 in Omicron spike_Dasatinib complex which experience fluctuations above 0.5 nm (Fig. 4). The gyration radius, which is a measure of structural compactness, was determined to be 1.791489131 ± 0.018121192 nm, 1.79507034 ± 0.02000475 nm, 1.834778215 ± 0.01906795 nm, and 1.792068042 ± 0.015354762 nm, respectively (Fig. 5). The results indicate that the compound binding causes a decrease in the structural compactness of the spike protein. The total solvent accessible surface area (the surface area of a protein that interacts with its solvent molecules) for free omicron spike protein, Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone complex was found to be 96.218537 ± 3.188253765 nm², 100.6188232 ± 3.602129296 nm², 99.58443457 ± 3.369326989 nm² and 98.73928472 ± 5.23296547 nm² respectively (Fig. 6). The increase in the total SASA upon interaction with the compounds indicate that the spike protein became less folded which enabled it to have more contact with the surrounding solvent molecules. The dynamics of the hydrogen bond network is crucial for understanding the protein stability in a solution. The intramolecular hydrogen bonds were found to be 124.8761239 ± 6.974570909, 116.2367632 ± 6.02129296 nm², 99.58443457 ± 3.369326989 nm² and 98.73928472 ± 5.23296547 nm² respectively (Fig. 7A). The results imply that the intramolecular hydrogen bonds within the omicron spike protein are decreased upon binding of the compounds. The intermolecular hydrogen bonds between the spike receptor and lead molecules were found to be 0.225774226 ± 0.450527496, 1.756243756 ± 1.04619476 and 1.623376623 ± 0.952372294 for Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone complex respectively (Fig. 7B) and these intermolecular hydrogen bonds help to contribute towards the stabilization of the complexes between the omicron spike protein and compounds.

The highly coordinated modes of fluctuations for Omicron spike and Omicron spike complexed with the top 3 ranked compounds were studied using essential dynamics (ED). A covariance matrix was generated for this by selecting the protein’s Cα atoms (N = 195). After diagonalizing the covariance matrix for free omicron spike protein, Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone, the trace of the covariance matrix was found to be 5.98045 nm², 5.0047 nm², and 4.0075 nm² respectively (Fig. 3A). This indicates that the compounds bind to the omicron spike protein, causing larger amplitudes of fluctuations. The average RMSD of the heavy atoms of the compounds-Abemaciclib, Dasatinib and Spiperone were found to be 0.396129844 ± 0.067303045 nm, 0.295270837 ± 0.09276118 nm and 0.752636825 ± 0.203613952 nm respectively (Fig. 3B) which suggests that the compounds did not undergo large conformational changes due to their stability within the active pocket of the omicron spike protein. RMSF is a measurement of a particle’s average variation from a reference position over time. The RMSF plot shows stable fluctuations in free omicron spike protein and its complexes except for positions 483–486 and 527 in Omicron spike_Spiperone complex and residue 519 in Omicron spike_Dasatinib complex which experience fluctuations above 0.5 nm (Fig. 4). The gyration radius, which is a measure of structural compactness, was determined to be 1.791489131 ± 0.018121192 nm, 1.79507034 ± 0.02000475 nm, 1.834778215 ± 0.01906795 nm, and 1.792068042 ± 0.015354762 nm, respectively (Fig. 5). The results indicate that the compound binding causes a decrease in the structural compactness of the spike protein. The total solvent accessible surface area (the surface area of a protein that interacts with its solvent molecules) for free omicron spike protein, Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone complex was found to be 96.218537 ± 3.188253765 nm², 100.6188232 ± 3.602129296 nm², 99.58443457 ± 3.369326989 nm² and 98.73928472 ± 5.23296547 nm² respectively (Fig. 6). The increase in the total SASA upon interaction with the compounds indicate that the spike protein became less folded which enabled it to have more contact with the surrounding solvent molecules. The dynamics of the hydrogen bond network is crucial for understanding the protein stability in a solution. The intramolecular hydrogen bonds were found to be 124.8761239 ± 6.974570909, 116.2367632 ± 6.02129296 nm², 99.58443457 ± 3.369326989 nm² and 98.73928472 ± 5.23296547 nm² respectively (Fig. 7A). The results imply that the intramolecular hydrogen bonds within the omicron spike protein are decreased upon binding of the compounds. The intermolecular hydrogen bonds between the spike receptor and lead molecules were found to be 0.225774226 ± 0.450527496, 1.756243756 ± 1.04619476 and 1.623376623 ± 0.952372294 for Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone complex respectively (Fig. 7B) and these intermolecular hydrogen bonds help to contribute towards the stabilization of the complexes between the omicron spike protein and compounds.

### Table 2

| Complex                             | Chain | No. of interface residues | Interface Area (Å²) | No. of salt bridges | No. of disulphide bonds | No. of hydrogen bonds | No. of non-bonded contacts |
|-------------------------------------|-------|---------------------------|---------------------|---------------------|------------------------|----------------------|---------------------------|
| ACE2:Omicron Spike protein complex  | A (ACE2) | 17 | 829 | 1 | – | 10 | 87 |
|                                     | B (Omicron spike protein) | 17 | 877 |                |                        |                      |                           |

Fig. 1. (A) Protein-protein complex between human ACE2 (pink) and omicron spike protein (aquamarine) and with the interface residues shown in yellow and orange spheres for ACE2 and spike protein respectively. (B) PDBSum analysis shows the interface residues and molecular interactions between ACE2 (Chain A) and omicron spike (Chain B).
6.31747 nm² and 7.47092 nm² respectively. The first few eigenvectors, out of a total of 585 (3 N), play a significant role in the system’s fluctuations. The eigenvalue curve of Omicron spike_Dasatinib and Omicron spike_Spiperone complex were steeper than that of free omicron spike protein except for Omicron spike_Abemaciclib indicating that fewer eigenvectors are required to comprehend the same degree of total mean square fluctuations (Fig. 8). The Eigenvector 1 (PC1) contribution towards fluctuations in free omicron spike protein and Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone was determined to be 1.74856 nm² (29.2379%), 1.39182 nm² (27.8103%), 2.592 nm² (41.0291%) and 2.07159 nm² (27.7287%), respectively, with corresponding cosine values of 0.683886, 0.845428, 0.794308 and 0.868173. In free omicron spike protein, Omicron spike_Abemaciclib, Omicron spike_Dasatinib and Omicron spike_Spiperone, respectively, eigenvector 2 (PC2) contribution to

**Fig. 2.** Left panel shows the binding poses of the top 3 lead molecules within the active pocket of Omicron spike protein (A) Abemaciclib (B) Dasatinib and (C) Spiperone where the spike protein is represented in grey ribbon and the lead molecules in a ball and stick representation. The right-hand panel shows the molecular interactions between lead molecules and spike protein. Here, the hydrogen bonds are shown in a green dashed line and hydrophobic interactions with red semi-arcs.
fluctuations was determined to be 0.851629 nm² (14.2402%), 0.799175 nm² (15.9684%), 0.614664 nm² (9.7296%) and 1.35787 nm² (18.1754%), with corresponding cosine values of 0.799175 nm² (15.9684%), 0.614664 nm² (9.7296%) and 0.851629 nm² (14.2402%)

Table 3
Physicochemical characteristics of selected compounds.

| Molecule Name             | MWa | Logb | HBAc | HBDd | TPSA(A²) | RBf | Druglikeness |
|---------------------------|-----|------|------|------|----------|-----|--------------|
| Salvianolic acid C        | 492.435 | 3.3063 | 10 | 6 | 177.89 | 8 | -3.5203      |
| Arbidol                   | 477.422 | 4.1689 | 5 | 1 | 80 | 8 | -1.164       |
| Cephartanilene            | 606.717 | 6.7524 | 8 | 0 | 61.68 | 2 | 4.58         |
| Abemaciclib               | 506.603 | 4.1154 | 8 | 1 | 75 | 7 | 6.2983       |
| Osimertinib               | 499.617 | 3.4175 | 9 | 2 | 87.35 | 10 | -5.4185      |
| Trimipramine              | 294.436 | 4.0102 | 2 | 0 | 64.48 | 4 | 4.0901       |
| Colforsin                 | 410.505 | 1.3206 | 10 | 7 | 113.29 | 3 | -4.6773      |
| Ingenol                   | 348.437 | 0.9134 | 5 | 4 | 97.99 | 1 | -0.49807     |
| Clofazimine               | 473.406 | 6.2781 | 4 | 1 | 39.99 | 4 | 1.9723       |
| Tafenoquine               | 463.498 | 4.7717 | 6 | 2 | 78.63 | 10 | -5.9887      |
| Balcanil                  | 446.363 | -0.0032 | 11 | 6 | 183.21 | 4 | 0.34679      |
| Baicalein                 | 270.239 | 2.3357 | 5 | 3 | 86.99 | 1 | 0.28194      |
| Cinanserin                | 340.49 | 3.5854 | 3 | 1 | 57.64 | 8 | 2.934        |
| GC373                     | 405.493 | 1.2677 | 8 | 4 | 116.76 | 11 | -13.113      |
| Boceprevir                | 519.684 | 3.1382 | 10 | 4 | 150.70 | 10 | -8.7582      |
| Bepridil                  | 366.547 | 4.4044 | 3 | 0 | 57.21 | 10 | 1.468        |
| Nelfinavir mesylate        | 567.792 | 4.4556 | 7 | 4 | 127.2 | 10 | 0.6687       |
| Z-FA-FMK                  | 386.422 | 2.1022 | 6 | 2 | 84.5 | 10 | -11.445      |
| Suramin                   | 1297.29 | -2.9082 | 29 | 12 | 534.03 | 16 | -1.2647      |
| Lopinavir                 | 628.811 | 4.847 | 9 | 4 | 120 | 15 | 6.5929       |
| Ritonavir                 | 720.957 | 4.7152 | 11 | 4 | 202.26 | 18 | -7.147       |
| Dipyridamole              | 504.634 | 0.7916 | 14 | 5 | 167.75 | 13 | 1.1609       |
| Dasatinib                 | 488.014 | 3.6259 | 9 | 3 | 134.75 | 7 | 8.0376       |
| Dronedarone               | 556.765 | 6.7266 | 7 | 1 | 97.23 | 17 | 0.70822      |
| Remdesivir                | 602.583 | 0.3048 | 14 | 4 | 213.36 | 13 | -21.381      |
| Favipiravir               | 157.104 | -1.7969 | 5 | 2 | 84.55 | 1 | 2.9436       |
| Dolutegravir              | 419.383 | 0.1208 | 8 | 2 | 99.18 | 3 | 5.5879       |
| -D-N4-Hydroxycytidine (EIDD-1931) | 259.217 | -3.1512 | 9 | 5 | 134.85 | 2 | -1.8924      |
| Tipranavir                | 602.672 | 5.9823 | 7 | 2 | 113.97 | 11 | -6.9229      |
| Saquinavir                | 670.852 | 2.836 | 11 | 5 | 166.75 | 13 | 1.609       |
| Atazanavir                | 704.866 | 3.3709 | 13 | 5 | 171.22 | 18 | -16.542      |
| Azithromycin              | 748.992 | 1.6569 | 14 | 5 | 180.08 | 7 | 13.854       |
| Spiperone                 | 395.476 | 3.0219 | 5 | 1 | 52.65 | 6 | 9.9352       |
| Alprostadil               | 354.485 | 4.045 | 5 | 3 | 94.83 | 13 | -16.472      |
| Ivermectin                | 875.102 | 4.7534 | 14 | 3 | 170.06 | 8 | 4.7349       |
| Peniclovir                | 253.281 | -1.6358 | 9 | 4 | 125.76 | 5 | 2.6783       |

Table 4
Average geometric properties of the systems with standard deviations in parentheses.

| Systems                  | RMSD² (nm) | RD² (nm) | Total SASA (Å²) | NHBS² Intramolecular | NHBS² Intermolecular |
|--------------------------|------------|----------|-----------------|-----------------------|----------------------|
| Free Omicron spike protein | 0.278901594 | 0.019166157 | 96.21862537 | 124.8761239 | - |
| Omicron                  | 0.328851582 | 0.035912944 | 1.79507034 | 100.618232 | 116.2367632 | 0.225774226 |
| Omicron                  | 0.308323815 | 0.057729586 | 1.8347762 | 99.5864453 | 121.2877123 | 1.750243756 |
| Omicron                  | 0.19084016 | 0.20361953 | 1.752068042 | 98.73928472 | 120.4625375 | 1.623176623 |

A. Bahadur Gurung, M. Ajmal Ali, M.S. Elshikh et al. Saudi Journal of Biological Sciences 29 (2022) 103297
4. Discussion

The increased number of new cases due to the new variant of concern, SARS-CoV-2 omicron, offers a challenge to global health systems as the world fights COVID-19. With a significant number of mutations and deletions, the fifth variant of concern is thought to be more infectious than previously found variants (Gao et al., 2021). More clinical evidence is needed to determine the virus’s actual pathogenicity, transmissibility, and ability to neutralize serum antibodies. Because there are no viable treatments for the previous variants as well, discovering therapeutic compounds for the omicron is a difficult challenge that will necessitate much scientific research. SARS-CoV-2 uses the spike glycoprotein to attach to the cellular receptor ACE2 to enter into the host cells and mediate its infectious cycle. Our current study is aimed at the identification of small molecules which can inhibit the interaction between omicron spike protein and ACE2. Using a set of 36 known antivirals for previous variants of SARS-CoV-2 and the recently solved experimental structure of omicron spike protein in complex with ACE2 (Han et al., 2022), we were able to evaluate whether these molecules could bind to the omicron spike protein. The protein–protein complex is stabilised by one salt bridge, ten hydrogen bonds, and 87 non-bonded interactions, according to PDBsum analysis. Abemaciclib, Dasatinib and Spiperone demonstrated a strong affinity for the omicron spike protein in molecular docking studies and their physicochemical property analysis revealed good drug-likeness scores. Abemaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that is currently being used in combination with an aromatase inhibitor or fulvestrant to treat endocrine sensitive and resistant metastatic luminal breast cancer, respectively (El Hachem et al., 2021). Dasatinib (Sprycel; Bristol-Myers Squibb) is a tyrosine kinase inhibitor that was approved by the US Food and Drug Administration (FDA) in June 2006 for the treatment of adults with chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia who had developed resistance or intolerance to previous therapy (Kantarjian et al., 2006). Spiperone is an antagonist for the dopamine D2 receptor. It is not used even though it has antipsychotic properties. It’s more commonly utilised as a pharmacological tool for studying neurotransmitter receptors (Davis, 2007). The molecular dynamics sim-
ulation results revealed stability of the trajectories through 100 ns and displayed differences in the geometric properties between the free omicron protein and its complexes with the lead molecules. Essential dynamics and entropic analysis also indicate the modulation of the structure of the spike protein by these lead molecules indicating that these compounds can impair the function of the omicron spike protein. To determine the binding strength and thermodynamic parameters of interaction between omicron spike protein and the lead compounds, experimental approaches such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) as well as spectroscopic techniques are recommended. Despite the fact that the current research is totally computational, the outcomes of our studies will aid in further experimental investigations and the development of therapies for SARS-CoV-2 omicron infections.

5. Conclusion

The extremely contagious nature of the novel omicron variant necessitates the development of effective drug molecules to combat its worldwide spread. We found three candidate drugs Abemaciclib, Dasatinib and Spiperone with high binding affinity for omicron spike glycoprotein and good drug-likeness scores using molecular docking and physicochemical property analysis. The binding of the lead compounds causes aberrations in the structural properties of the omicron spike protein as revealed from molecular dynamics simulation investigations. These compounds could be developed into SARS-CoV-2 omicron entry inhibitors, which would help to reduce infection and spread.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Fig. 7. Hydrogen bond analysis of free omicron spike protein and omicron spike-ligand complexes (A) intramolecular protein hydrogens (B) intermolecular protein-ligand hydrogen bonds.

Fig. 8. Eigenvalue vs eigenvector index plot of free omicron spike protein and omicron spike-ligand complexes with the inset depicting cumulative contribution to overall fluctuation versus eigenvector index. The figure only shows the first fifty eigenvectors out of 585 eigenvectors (3 N where N = 195).

Fig. 9. Plot of two-dimensional projections of PC1 and PC2 for free omicron spike protein and omicron spike-ligand complexes.
Acknowledgements

The authors would like to extend their sincere appreciation to the Researchers Supporting Project number (RSP-2021/306), King Saud University, Riyadh, Saudi Arabia.

References

Amadei, A., Linssen, A.B.M., Berendsen, H.J.C., 1993. Essential dynamics of proteins. Proteins Struct. Funct. Bioinforma. 17 (4), 412–425. https://doi.org/10.1002/prot.340170408.

Andricioaei, I., Karplus, M., 2001. On the calculation of entropy from covariance matrices of the atomic fluctuations. J. Chem. Phys. 115 (14), 6289–6292. https://doi.org/10.1063/1.1401821.

Davis, C., 2007. Spiperone. In: Enna, S.J., Bylund, D.B. (Eds.), XPharm: The Comprehensive Pharmacology Reference. Elsevier, New York, pp. 1–3.

El Hachem, G., Gombos, A., Awada, A., 2021. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Expert Rev. Anticancer Ther. 21 (1), 81–92.

Gao, S.-J., Guo, H., Luo, G., 2021. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J. Med. Virol. 94 (4), 1255–1256.

GISAID. (2021). Tracking of Variants. https://www.gisaid.org/hcov19-variants/ Date accessed: November 30, 2021.

Greaney, A.J., Starr, T.N., Gilchuk, P., Zost, S.J., Binshtein, E., Loes, A.N., Hilton, S.K., Huddleston, J., Eguia, R., Crawford, K.H.D., Diogens, A.S., Nargi, R.S., Sutton, R.E., Suryadvara, N., Rothlauf, P.W., Liu, Z., Whelan, S.P.J., Carnahan, R.H., Crowe, J.E., Bloom, J.D., 2021. Complete mapping of mutations to the SARS-CoV-2 spike
receptor-binding domain that escape antibody recognition. Cell Host Microbe 29 (1), 44–57.e9.

Gurung, A.B., 2020. In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors. Gene Rep. 21, 100860. https://doi.org/10.1016/j.genrep.2020.100860.

Halgren, T.A., 1996. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17, 490–519. https://doi.org/10.1002/(SICI)1096-987X(199604)17:5<490::AID-JCC1>3.0.CO;2-P.

Han, P., Li, L., Liu, S., Wang, Q., Zhang, D.I., Xu, Z., Han, P., Li, X., Peng, Q.I., Su, C., Huang, B., Li, D., Zhang, R., Tian, M., Fu, L., Gao, Y., Zhao, X., Liu, K., Qi, J., Gao, G.F., Wang, P., 2022. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 185 (4), 630–640.e10.

Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M., Ludden, C., Reeve, R., Rambaut, A., Peacock, S.J., Robertson, D.L., 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19 (7), 409–424.

Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., 2008. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435–447. https://doi.org/10.1021/ct700301q.

Kantarjian, H., Jabbour, E., Grimley, J., Kirkpatrick, P., 2006. Dasatinib. Nat. Rev. Drug Discov. 5 (9), 717–718.

Karim, S.S.A., Karim, Q.A., 2021. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398 (10317), 2126–2128.

Kim, S., Thiessen, P.A., Bolton, E.E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B.A., Wang, J., Yu, B.o., Zhang, J., Bryant, S.H., 2016. PubChem Substance and Compound databases. Nucleic Acids Res 44 (D1), D1202–D1213. https://doi.org/10.1093/nar/gkv951.

Kirchdoerfer, R.N., Cottrell, C.A., Wang, N., Pallesen, J., Yassine, H.M., Turner, H.L., Corbett, K.S., Grahant, B.S., McLellan, J.S., Ward, A.B., 2016. Pre-fusion structure of a human coronavirus spike protein. Nature 531 (7592), 118–121.

Laskowski, R.A., 2009. PDBsum new things. Nucleic Acids Res. 37 (Database), D355–D359. https://doi.org/10.1093/nar/gkn860.

Laskowski, R.A., Swindells, M.B., 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51 (10), 2778–2786. https://doi.org/10.1021/ci200227u.

Lipinski, C.A., 2004. Lead- and drug-like compounds: the rule-of-five revolution. J. Med. Chem. 45 (12), 2615–2623.

Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., Olson, A.J., 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30 (16), 2785–2791. https://doi.org/10.1002/jcc.21256.

O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., 2011. Open Babel: An open chemical toolbox. J. Cheminform. 3, 33. https://doi.org/10.1016/j.apsb:2021.06.016.

Ou-Yang, S.-S., Lu, J.-Y., Kong, X.-Q., Liang, Z.-L., Luo, C., Jiang, H., 2012. Computational drug discovery. Acta Pharmacol. Sin. 33 (9), 1131–1140.

Pants, J.-E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray, P.B., Gallagher, T., 2016. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. 113 (43), 12262–12267.

Rastelli, G., Rio, A.D., Deglieposti, G., Sgobba, M., 2010. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J. Comput. Chem., NA–NA https://doi.org/10.1002/jcc.21372.

Sander, T., Freyss, J., von Korff, M., Rufen, C., 2015. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. 55 (2), 460–473. https://doi.org/10.1021/ci500588x.

Tortorici, M.A., Veesler, D., 2019. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116.

Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W., Kopple, K.D., 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (12): 2615–2023.

Walls, A.C., Park, Y.-J., Tortorici, M.A., Veesler, D., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181 (2), 281–292.e6.

Walls, A.C., Tortorici, M.A., Bosch, B.-J., Frenz, B., Rottier, P.J.M., DiMaio, F., Rey, F.A., Veesler, D., 2016. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531 (7592), 114–117.

World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. November 26, 2021. https://www.who.int/news/item/26-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

Xiang, R., Yu, Z., Wang, Y., Wang, L., Huo, S., Li, Y., Liang, R., Hao, Q., Ying, T., Gao, Y., Yu, F., Jiang, S., 2021. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2021.06.016.